BenzingaOctober 14, 2026 at 9:56 AM NY13 Days Ago
Citigroup Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $320
Citigroup analyst Eric Joseph maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $340 to $320.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
